Literature DB >> 29268321

The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis.

Rossana Berardi1, Silvia Rinaldi1.   

Abstract

Entities:  

Year:  2017        PMID： 29268321      PMCID： PMC5723761          DOI： 10.21037/jtd.2017.09.130

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.

Authors:  Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

4.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

Authors:  Yonit Lavin; Soma Kobayashi; Andrew Leader; El-Ad David Amir; Naama Elefant; Camille Bigenwald; Romain Remark; Robert Sweeney; Christian D Becker; Jacob H Levine; Klaus Meinhof; Andrew Chow; Seunghee Kim-Shulze; Andrea Wolf; Chiara Medaglia; Hanjie Li; Julie A Rytlewski; Ryan O Emerson; Alexander Solovyov; Benjamin D Greenbaum; Catherine Sanders; Marissa Vignali; Mary Beth Beasley; Raja Flores; Sacha Gnjatic; Dana Pe'er; Adeeb Rahman; Ido Amit; Miriam Merad
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

5.  Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Authors:  Solange Peters; Scott Gettinger; Melissa L Johnson; Pasi A Jänne; Marina C Garassino; Daniel Christoph; Chee Keong Toh; Naiyer A Rizvi; Jamie E Chaft; Enric Carcereny Costa; Jyoti D Patel; Laura Q M Chow; Marianna Koczywas; Cheryl Ho; Martin Früh; Michel van den Heuvel; Jeffrey Rothenstein; Martin Reck; Luis Paz-Ares; Frances A Shepherd; Takayasu Kurata; Zhengrong Li; Jiaheng Qiu; Marcin Kowanetz; Simonetta Mocci; Geetha Shankar; Alan Sandler; Enriqueta Felip
Journal:  J Clin Oncol       Date:  2017-06-13       Impact factor: 44.544

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Bailiang Li; Yi Cui; Maximilian Diehn; Ruijiang Li
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

8.  CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.

Authors:  Erna-Elise Paulsen; Thomas K Kilvaer; Mehrdad Rakaee; Elin Richardsen; Sigurd M Hald; Sigve Andersen; Lill-Tove Busund; Roy M Bremnes; Tom Donnem
Journal:  Cancer Immunol Immunother       Date:  2017-07-13       Impact factor: 6.968

9.  PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

Authors:  Yayi He; Leslie Rozeboom; Christopher J Rivard; Kim Ellison; Rafał Dziadziuszko; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Med Sci Monit       Date:  2017-03-09

10.  Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.

Authors:  Rossana Berardi; Silvia Rinaldi; Matteo Santoni; Thomas Newsom-Davis; Michela Tiberi; Francesca Morgese; Miriam Caramanti; Agnese Savini; Consuelo Ferrini; Mariangela Torniai; Ilaria Fiordoliva; Marc Bower; Stefano Cascinu
Journal:  Oncotarget       Date:  2016-05-03
View more
  1 in total

Review 1.  Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies.

Authors:  Jesus Rodriguez-Pascual; Angel Ayuso-Sacido; Cristobal Belda-Iniesta
Journal:  Cancer Drug Resist       Date:  2019-12-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.